Quad Cities Investment Group LLC purchased a new position in Johnson & Johnson (NYSE:JNJ) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,607 shares of the company’s stock, valued at approximately $464,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Stelac Advisory Services LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $108,000. Princeton Capital Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at approximately $141,000. Smart Portfolios LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at approximately $150,000. Signition LP acquired a new stake in Johnson & Johnson in the 1st quarter valued at approximately $204,000. Finally, Fenimore Asset Management Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $217,000. 66.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of JNJ stock traded down $0.25 during mid-day trading on Friday, hitting $139.10. 4,308,720 shares of the stock traded hands, compared to its average volume of 6,949,498. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The stock has a market cap of $370.70 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.04. The company had revenue of $20.83 billion for the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $1.83 EPS. Equities research analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s payout ratio is 49.32%.
Several analysts recently commented on the company. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research report on Friday, September 14th. Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Sanford C. Bernstein initiated coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 target price on the stock. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $143.91.
In related news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.